A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease
← catalyst calendarNCT07111013 · readout ≤ 254 d
Sponsored by Bausch & Lomb Incorporated (industry) · BLCO — their whole pipeline →.
Phase
Phase 3
Status
Withdrawn
Study type
Interventional
Design
Na · None · Treatment
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Business Decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Dec 2025 | estimated | When the study began enrolling |
| Primary completion | Apr 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dry Eye Disease
Intervention
- Drug: Lifitegrast/perfluorohexyloctane (PFHO)
Primary outcome
what the primary-completion date above is the date OFIncidence of Treatment Emergent Adverse Events
measured Assessed for 12 months
Permalink · BLCO's whole pipeline · Catalyst calendar · Every registered study · What changed